| Title |
Preference-Based Health-Related Quality-of-Life Outcomes in Children with Autism Spectrum Disorders
|
|---|---|
| Published in |
PharmacoEconomics, December 2012
|
| DOI | 10.2165/11597200-000000000-00000 |
| Pubmed ID | |
| Authors |
J. Mick Tilford, Nalin Payakachat, Erica Kovacs, Jeffrey M. Pyne, Werner Brouwer, Todd G. Nick, Jayne Bellando, Karen A. Kuhlthau |
| Abstract |
Cost-effectiveness analysis of pharmaceutical and other treatments for children with autism spectrum disorders (ASDs) has the potential to improve access to services by demonstrating the value of treatment to public and private payers, but methods for measuring QALYs in children are under-studied. No cost-effectiveness analyses have been undertaken in this population using the cost-per-QALY metric. |
Mendeley readers
The data shown below were compiled from readership statistics for 180 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| United States | 2 | 1% |
| Australia | 1 | <1% |
| Unknown | 177 | 98% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Researcher | 32 | 18% |
| Student > Master | 20 | 11% |
| Student > Ph. D. Student | 14 | 8% |
| Student > Doctoral Student | 14 | 8% |
| Student > Postgraduate | 10 | 6% |
| Other | 45 | 25% |
| Unknown | 45 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Psychology | 36 | 20% |
| Medicine and Dentistry | 27 | 15% |
| Nursing and Health Professions | 18 | 10% |
| Social Sciences | 12 | 7% |
| Economics, Econometrics and Finance | 11 | 6% |
| Other | 23 | 13% |
| Unknown | 53 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 10. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 17 October 2022.
All research outputs
#3,415,054
of 25,373,627 outputs
Outputs from PharmacoEconomics
#322
of 1,992 outputs
Outputs of similar age
#32,965
of 289,094 outputs
Outputs of similar age from PharmacoEconomics
#23
of 280 outputs
Altmetric has tracked 25,373,627 research outputs across all sources so far. Compared to these this one has done well and is in the 86th percentile: it's in the top 25% of all research outputs ever tracked by Altmetric.
So far Altmetric has tracked 1,992 research outputs from this source. They typically receive more attention than average, with a mean Attention Score of 7.6. This one has done well, scoring higher than 82% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 289,094 tracked outputs that were published within six weeks on either side of this one in any source. This one has done well, scoring higher than 88% of its contemporaries.
We're also able to compare this research output to 280 others from the same source and published within six weeks on either side of this one. This one has done particularly well, scoring higher than 91% of its contemporaries.